Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback